Pramipexole ER vs. Placebo in Fibromyalgia

Summary

The primary objective of this study is to assess the efficacy and safety of an extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment of fibromyalgia. The objective of the open-label phase is to assess the safety profile and effect of Pramipexole (PPX) extended-release (ER) in fibromyalgia patients over a 24-week period.

Timeline

Start

2008-07

Primary completion

2008-11

Completion

—

Drugs

Indications